NetworkNewsBreaks – Soligenix Inc (SNGX) CEO Hig
Post# of 110

Soligenix (SNGX) Chairman and CEO Dr. Christopher Schaber joined IBN’s BioMedWire Podcast to discuss the company’s two-pronged business model, robust late-stage pipeline, and ongoing clinical trials. Schaber emphasized Soligenix’s focus on rare disease therapeutics and its Public Health Solutions segment, which has received over $60 million in non-dilutive U.S. government funding. He also outlined near-term milestones, including a confirmatory Phase 3 trial, active partnership discussions, and continued pursuit of strategic opportunities.
For more information, visit the company’s website at at https://www.soligenix.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer

